Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic Rochester

Neither a doctor nor a teaching hospital

Research payments

$45,377,410

3,305 payments

Through program year 2025, Mayo Clinic Rochester is reported as receiving $45,377,410 in research payments, across 3,305 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $7,469,773 781
2024 Research $7,086,116 447
2023 Research $6,326,648 362
2022 Research $5,411,873 389
2021 Research $6,541,887 543
2020 Research $5,756,931 379
2019 Research $6,784,183 404

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $8,187,672 499 payments
  2. Merck Sharp & Dohme Corporation $7,180,398 111 payments
  3. Genentech, Inc. $4,924,671 253 payments
  4. Janssen Research & Development, LLC $3,324,259 58 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $3,150,775 135 payments
  6. AbbVie, Inc. $2,140,232 163 payments
  7. Incyte Corporation $1,931,954 795 payments
  8. Gilead Sciences, Inc. $1,916,324 157 payments
  9. Amgen Inc. $1,591,128 26 payments
  10. Deciphera Pharmaceuticals Inc. $889,373 377 payments
Studies the money was for Research payments · program years 2019–2025
  1. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-resistant Differentiated Thyroid Cancers $2,822,201 27 payments
  2. Stegall_A Phase III, Prospective, Open-Label, Randomized Clinical Trial Evaluating the Augmenting of Anti-SARS-CoV2 Immunity in Kidney Transplant Recipients via a Heterologous Additional Dose with Janssen Ad26.CoV2.S vaccine $2,716,653 32 payments
  3. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy $1,798,572 36 payments
  4. Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Patients with High Risk Smoldering Multiple Myeloma (A Black Swan Research Initiative cure bas $1,063,850 4 payments
  5. A Phase II, Open-Label, Multi-Center Trial of PDS0101 ImmunoMAPK-RDOTAP,HPV-16 E6 & E7 peptides and Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 HPV16 Infection after Failure with Platinum-Based Chemotherapy $1,026,703 2 payments
  6. Serum and CSF $967,437 6 payments
  7. PR3 AAV Resilient Remission or PRRR $872,345 13 payments
  8. A phase III randomized trial of Blinatumomab for newly diagnosed bcr-abl-negative lineage acute lymphoblastic leukemia in adults $839,894 2 payments
  9. HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) $829,108 32 payments
  10. HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) $773,777 50 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $180,247 21 payments
  2. Non-patient care $7,950 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record